Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceSin categoríaVideos

EMA CHMP gives positive opinion on CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myeloma

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has given a positive recommendation for the extension of the marketing authorisation for idecabtagene vicleucel (ide-cel), a CAR-T treatment marketed by BMS as Abecma®. Ide-cel is currently approved for the treatment of patients with relapsed and refractory myeloma, who have…

Read more

MPE announces partnership in EU consortium project CERTAINTY: advancing cancer care through virtual twins in personalised immunotherapy

MPE announces partnership with an international team, including representatives from scientific, industry, and healthcare sectors, as part of the EU-funded research project CERTAINTY, which began in December 2023. The EU consortium “CERTAINTY – A cellular immunotherapy virtual twin for personalized cancer treatment” is being funded by the European Union with almost EUR 10 million over…

Read more

ASH 2023 | Myeloma and AL amyloidosis updates

Myeloma Patients Europe (MPE) attended the 65th American Society of Hematology (ASH) Annual Meeting, the largest haematology congress, held from 9 to 12 December in San Diego (United States). MPE has interviewed haematology experts to summarise the latest myeloma and AL amyloidosis updates.   Prof. Dr. Michel Delforge, Department of Haematology, University Hospital Leuven, Belgium, explains…

Read more

EMA CHMP confirms recommendation for non-renewal of Blenrep marketing authorisation

The European Medicines Agency (the EU medicines regulator) Committee for Medicinal Products for Human Use (CHMP) has today confirmed their earlier recommendation to not renew marketing authorisation for belamaf mafadotin (Blenrep®). The confirmation follows a review of the CHMP decision, requested by the manufacturer GSK. MPE Co-Chief Executive Officer, Kate Morgan, commented: “The final recommendation…

Read more

The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myeloma

The European Commission has granted conditional marketing authorisation for elranatamab, also known as Elrexfio® marketed by the pharmaceutical company Pfizer. This follows an earlier positive recommendation from the European Medicines Agency (EMA – the EU drug licensing body) Committee for Medicinal Products for Human Use (CHMP), after which the European Commission had 60 days to…

Read more
January

February 2026

March
MO
TU
WE
TH
FR
SA
SU
26
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
1
Events for 1st February
No Events
Events for 2nd February
No Events
Events for 3rd February
No Events
Events for 4th February
No Events
Events for 5th February
No Events
Events for 6th February
No Events
Events for 7th February
No Events
Events for 8th February
No Events
Events for 9th February
No Events
Events for 10th February
No Events
Events for 11th February
No Events
Events for 12th February
No Events
Events for 13th February
No Events
Events for 14th February
No Events
Events for 15th February
No Events
Events for 16th February
No Events
Events for 17th February
No Events
Events for 18th February
No Events
Events for 19th February
No Events
Events for 20th February
No Events
Events for 21st February
No Events
Events for 22nd February
No Events
Events for 23rd February
No Events
Events for 24th February
No Events
Events for 25th February
No Events
Events for 26th February
No Events
Events for 27th February
No Events
Events for 28th February
No Events